The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...

Gene-editing assets may be the next additions to big pharma shopping lists as gene therapies are now becoming core modalities alongside small molecules and mAbs, according to Sandy Macrae, who anticipates...

While the pandemic has put much of normal life on hold, the biotech industry has continued to hum along, funding and advancing R&D while simultaneously ushering the world into the post-COVID era one...

Merck & Co. continues to build out its immuno-oncology pipeline beyond Keytruda, this time via a deal with David Campbell’s California start-up Janux that increases the pharma’s presence in the...

On the latest edition of the BioCentury this Week podcast, BioCentury editors discuss the latest advances and setbacks among COVID-19 vaccines in the wake of FDA’s emergency use authorization on Friday for Pfizer and BioNTech’s...

CAR T manufacturers and payers are still negotiating access for B cell lymphoma patients without other treatment options, but that hasn’t stopped companies from pressing on into earlier lines of treatment....

Vertex, CRISPR update long-term data for edited cell therapyCRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) showed seven transfusion-dependent β thalassemia patients in the CLIMB-Thal-111 study remain transfusion-free for up to 18 months following CTX001...

Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...

Via a deal with Atara, Bayer’s latest additions to its new gene and cell therapy unit are an allogeneic CAR T treatment that the pharma hopes can treat solid tumors — and an autologous version that...